A Longitudinal Observational Study of Patients Undergoing Therapy for IMISC

N/AActive Not RecruitingNCT03661866

Target PharmaSolutions, Inc.15,000 enrolled

Overview

TARGET-DERM is a longitudinal, observational study of adult and pediatric patients being managed for Atopic Dermatitis and other Immune-Mediated Inflammatory Skin Conditions (IMISC) in usual clinical practice. TARGET-DERM will create a research registry of patients with IMISC within academic and community real-world practices in order to assess the safety and effectiveness of current and future therapies.

Study Type

OBSERVATIONAL

Enrollment

15,000

Conditions

Atopic Dermatitis Alopecia Areata Hidradenitis Suppurativa Vitiligo Psoriasis Chronic Spontaneous Urticaria

Eligibility

Sex: ALL

Medical Language ↔ Plain English

Inclusion Criteria: * 1\. Adults and children (all ages) with Atopic Dermatitis or other Immune-mediated Inflammatory Skin Conditions been prescribed any dermatologic treatment. * 2\. Participant has plans for future visits at the site for continued management of IMISC. Exclusion Criteria: * 1\. Inability to provide written informed consent/assent. * 2\. Subjects participating in any interventional study or trial for IMISC treatment trial at the time of enrollment. Patients may be enrolled in TARGET-DERM once participation in the trial is complete. Note: Participants may be enrolled in other registries or studies where IMISC treatment outcomes are observed and/or reported (such as center-based registries).

Locations (62)

Clear Dermatology & Aesthetics Center/Investigative MD

Scottsdale, Arizona, United States

Johnson Dermatology

Fort Smith, Arkansas, United States

University of Arkansas for Medical Sciences

Little Rock, Arkansas, United States

Arkansas Dermatology

Little Rock, Arkansas, United States

First OC Dermatology

Fountain Valley, California, United States

Outcomes

Primary Outcomes

Characterize IMISC Treatment Regimens in Clinical Practice

Enable characterization of IMISC disease activity and comorbid medical conditions over time.

Time frame: 25 Years

Evaluate Patient Outcomes in Clinical Practice

Enable characterization of IMISC disease activity and comorbid medical conditions over time.

Time frame: 25 Years

Evaluate Adverse Events of IMISC and treatment in Clinical Practice

Enable characterization of IMISC disease activity and comorbid medical conditions over time.

Time frame: 25 Years

Secondary Outcomes

Evaluate the relationship between IMISC and comorbid medical conditions

Inform clinical practice by identifying the occurrence and impact of comorbid medical conditions on treatment regimens, utilize patient reported outcomes, and evaluate patient support programs.

Time frame: 25 Years

Evaluate Patient Reported Outcome (PRO) measures

Inform clinical practice by identifying the occurrence and impact of comorbid medical conditions on treatment regimens, utilize patient reported outcomes, and evaluate patient support programs.

Time frame: 25 Years

Evaluate outcomes related to Patient Support Programs (PSPs)

Inform clinical practice by identifying the occurrence and impact of comorbid medical conditions on treatment regimens, utilize patient reported outcomes, and evaluate patient support programs.

Time frame: 25 Years